At a glance
- Originator Tamarkin Pharmaceutical Innovation
- Class Antipsoriatics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acne; Hair disorders; Psoriasis; Seborrhoeic dermatitis
Most Recent Events
- 25 Aug 2004 This compound is still in active development
- 28 Feb 2003 Phase-II clinical trials in Hair disorders (Topical)
- 28 Feb 2003 Phase-II clinical trials in Psoriasis (Topical)